Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

Status Active, not recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma

Clinical Trial Description

There have been no standard treatment in non-clear cell renal cell carcinoma. Retrospective studies showed sunitinib or sorafenib might be active in non-clear cell renal cell carcinoma, especially papillary type and chromophobe type.

This study is to evaluate efficacy and safety of sunitinib in this group of patients. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01219751
Study type	Interventional
Source	Asan Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 2008
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00930033` - Clinical Trial to Assess the Importance of Nephrectomy	Phase 3
Recruiting	`NCT05863351` - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study	Phase 3
Not yet recruiting	`NCT06284564` - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)	Phase 2
Completed	`NCT00414765` - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma	Phase 4
Active, not recruiting	`NCT03149822` - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT03647878` - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed	`NCT01517243` - Phase II Study of Alternating Sunitinib and Temsirolimus	Phase 2
Withdrawn	`NCT03927248` - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer	Phase 1/Phase 2
Terminated	`NCT02122003` - Second Line Sorafenib After Pazopanib in Patients With RCC	Phase 2
Completed	`NCT01182142` - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients	Phase 2
Completed	`NCT00630409` - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Completed	`NCT04076787` - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting	`NCT04467021` - Cancer and Blood Pressure Management, CARISMA Study	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT02282579` - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Completed	`NCT01731158` - Sequential Therapy in Metastatic Renal Cell Carinoma	Phase 2
Terminated	`NCT02071641` - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma	Phase 2
Terminated	`NCT01342627` - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT01274273` - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer	Phase 2